File(s) not publicly available
Etanercept as a salvage treatment for refractory aplastic anemia
journal contribution
posted on 2023-06-08, 13:26 authored by Carlo Dufour, Raffaella Giacchino, Pietro Ghezzi, Rossella Tonelli, Elisa Ferretti, A Pitto, Vito Pistoia, Tiziana Lanza, Johanna SvahnAbout 10-15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.
History
Publication status
- Published
Journal
Pediatric Blood & CancerISSN
1545-5009Publisher
Wiley-BlackwellExternal DOI
Issue
4Volume
52Page range
522-525Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2012-11-02Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC